Breast augmentation, implants and Australian regulation

Breast augmentation is the operation people think they already understand. A device goes in; a cup size comes out. That sentence is how advertising used to work, and it is one reason Australian regulators spent the last decade tightening the language around both the devices and the people who implant them. An implant is not a fashion accessory. It is a Class III medical device sitting in a pocket next to breast tissue, muscle and, over a lifetime, mammograms. It can rupture. It can be enveloped in a tight scar. It can, rarely, be associated with a lymphoma. It will not, on any honest consent form, stay out of the conversation after the first post-operative visit.

This explainer is for Australian readers preparing a consultation. It is not a recommendation to have implants, and it does not name a brand. Prescription-only medicines are outside the scope; we do not advertise those either. For the neighbouring operations — lift, reduction, explant — see the breast surgery hub.

What the TGA is doing in the room even if no one says its name

The Therapeutic Goods Administration regulates the supply of medical devices in Australia. Breast implants sit at the high-risk end of that system. A device must be included in the Australian Register of Therapeutic Goods, or otherwise lawfully supplied, before a hospital should be opening the box. When evidence changes, the TGA issues safety communications, imposes conditions, or removes products. Readers who want the primary source should use the TGA website, not a clinic brochure.

That regulatory fact has a practical consequence for consent. You are entitled to know, in general terms, what class of device is proposed (for example, a silicone-gel implant of a given surface type), how long that design has been in use, and how you would be reached if a hazard alert were issued. You are entitled to the sticker page — the labels that identify the device — and to a copy of the operation record. “Trust us, we use the good ones” is not a substitute. This journal will not rank brands or reproduce a supplier’s marketing claims.

Surface — smooth or textured, and the various degrees of texture that have existed — is part of the risk conversation because the rare lymphoma discussed below has been observed more often in association with textured devices. Fill (silicone gel of varying cohesiveness, or saline) and shape (round or anatomical) are the other axes. Each axis is a trade-off in feel, visibility of rippling, rotation risk and the evidence base, not a ladder from “basic” to “premium”. Anyone selling an implant as a lifestyle upgrade is advertising a regulated device as if it were a handbag.

Registries are not warranties

Australia’s Australian Breast Device Registry exists so that devices, operations and selected outcomes can be tracked at a population level. Similar registries operate in other countries; they are how patterns — including rare ones — become visible. A surgeon should explain whether they contribute, what is recorded, and how your privacy is handled. Participation is a quality-and-safety habit. It is not a guarantee that your implant will “last” a advertised number of years.

Implants are not lifetime devices in the sense of a set-and-forget joint replacement, and even joint replacements are not that. Some people have no further breast-implant operation for a long time. Some return earlier because of rupture, contracture, malposition, pain, a size they no longer want, or a safety notice. The honest unit of time is “unknown, with a non-zero chance of further surgery”. Quotes that treat a single theatre booking as the last breast operation a person will ever fund are not quotes. They are wishes.

Keep your own file. Device stickers, the name of the hospital, the date, and the name of the operating practitioner (checked on the Ahpra register) are more useful in a decade than a remembered brand name. If you change cities or surgeons, that file travels with you.

BIA-ALCL, contracture, rupture — risks to discuss, not dramas to binge

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare T-cell lymphoma that can develop in the fluid or capsule around an implant. Australian and international regulators have published on it; the TGA has restricted or removed some textured devices over the years as the evidence accumulated. The absolute risk is low. Low is not zero. The consent conversation should include what symptoms to take seriously years later: new swelling of a breast that had been stable, a fluid collection, a lump in the breast or armpit, or a change in the shape of the capsule. Those symptoms have many causes. They are a reason for clinical assessment and, where indicated, ultrasound, cytology and a specialist referral — not a reason to diagnose yourself at midnight.

BIA-ALCL is not breast cancer in the usual ductal or lobular sense, which is precisely why people miss it if they only think in mammogram terms. It is also not a reason for this journal to tell you to have implants removed “just in case”. Risk management is individual. It includes the type of device you already have, whether you have symptoms, and a discussion you can only have with a practitioner who has examined you.

Capsular contracture is the more common long-term nuisance: the scar the body forms around the implant tightens and can make the breast feel firm, look distorted, or ache. Grades are used in clinics; you do not need the scale to understand the idea. Further surgery is sometimes discussed. Rupture of a silicone implant may be silent. Imaging — ultrasound, MRI, or both, depending on the question and the service — is how integrity is investigated. Saline ruptures deflate in a more obvious way. None of these events is a moral failure. They are device-and-biology events.

Infection, haematoma, altered nipple or breast sensation, visible rippling, malposition, animation deformity when the implant sits under muscle, and dissatisfaction with size are the rest of the ordinary list. Anaesthetic and general surgical risks apply. Combining augmentation with a lift changes the list again; see our mastopexy explainer and, for later operations, implant revision and explant.

Sizing is a process, not a shopping cart

People arrive with a cup size, a photograph, or a sentence about looking “in proportion”. Cup size is a clothing convention, not a surgical unit. Surgeons talk in tissue coverage, base width, and the volume a particular chest can hide without the implant shouting through the skin. Trying on external sizers, looking in a mirror, and sometimes using three-dimensional photographs are ways of testing that conversation. They are not a contract that a theatre photograph will match a phone photograph.

Under-muscle, in-front-of-muscle, and dual-plane pockets are technical choices with different implications for pain in the first days, for animation, and for mammography. Incisions — inframammary fold, around the areola, or others — trade scar visibility against access and, in some discussions, against breastfeeding and sensation risk. There is no scarless augmentation. There is only a scar you have agreed to.

Lifestyle belongs in the sizing hour. Distance running, weight training, and occupations that load the chest wall do not make surgery impossible; they change what “a result I can live with” means. Weight change after surgery will change the look of any breast, implanted or not. Pregnancy and breastfeeding after implants are possible for many people and uncertain for some; that uncertainty should be spoken, not buried under a brochure paragraph.

Screening, follow-up and the long middle of ownership

Implants do not exempt anyone from breast-cancer screening. They complicate the pictures. A screening service told in advance can adapt the technique. Self-awareness still matters: a new lump, skin dimpling, nipple inversion or bloodstained discharge is investigated because it is a breast symptom, not because of the device. People with a strong family history or a known genetic risk need that conversation to include a breast-cancer specialist, not only an implant surgeon.

Follow-up after the early post-operative visits is easy to drop. It should not be. A plan for when to image a silent implant, whom to see if a late swelling appears, and how to interpret a TGA notice is part of owning the device. If the original surgeon retires or you move, the registry and your sticker page are how the next practitioner starts.

Recovery windows, as ever, are ranges. Desk work is often discussed in the order of one to two weeks; driving, gym work and upper-body loading later, commonly in a four-to-six-week band or beyond, depending on the pocket and the job. Those figures are not promises. Haematoma, infection or a wound problem resets them. Urgent symptoms — sudden swelling, fever, breathlessness, chest pain — are 000 or emergency-department matters, not Instagram matters. Healthdirect (1800 022 222) can help triage if you cannot reach the treating team.

Augmentation is a regulated operation with a regulated device and a long tail of follow-up. It can be an appropriate choice for some people after screening, sizing and a cooling-off period that Ahpra’s cosmetic-surgery rules expect. It is never a personality, a relationship or a career, and it is never something this journal will describe as a before-and-after. If a consult feels like retail, leave and take the device questions to someone who is prepared to talk about lymphoma, rupture and the registry before they talk about a cup size.